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abstract

PURPOSE Diffuse large B-cell lymphoma (DLBCL) is the most commonly diagnosed non-Hodgkin lymphoma in
adults in Kenya. Cell of origin (COO) and double expression of MYC and BCL2 are two important prognostic
factors for DLBCL. A small subset (5% to 10%) of DLBCL cases show positivity for CD5 and are associated with
poor prognosis, whereas CD30 antigen, seen in up to 10% of cases, may be a useful target for therapy. We
sought to determine the prevalence of MYC/BCL2 double expression, COO, and proportion of Epstein-Barr virus
positivity among patients with DLBCL diagnosed at a tertiary referral laboratory in Kenya.
PATIENTS AND METHODS All cases of DLBCL diagnosed from 2012 through 2015 in our pathology department
were analyzed. Tumor tissue microarray sections were stained with CD20, CD3, CD5, CD30, BCL2, BCL6, CD10,
MUM1, MYC, and Ki67, classiﬁed for COO on the basis of the Hans algorithm, and subjected to Epstein-Barr
virus-encoded small RNAs in situ hybridization.
RESULTS Among 165 DLBCL cases, the median age was 50 years, and there was no sex predilection. Only 18
(10.9%) cases showed double expression for MYC and BCL2. Germinal center B (GCB)-cell type DLBCL
accounted for 67 cases (40.6%) and 97 cases (59.4%) were classiﬁed as non-GCB. The mean Ki67 proliferation
index was signiﬁcantly higher in the double-expressing (45%) and non-GCB groups (36%) compared with the
non–double-expressing group (29%) and GCB group (26%). Sixteen cases (9.7%) were Epstein-Barr virusencoded small RNAs positive, 12 (75%) of which were non-GCB.
CONCLUSION DLBCL in Kenya is seen in much younger patients with the poor prognostic non–GCB-type accounting for 59.4% of cases. MYC and BCL2 double expression was seen in fewer tumors than reported in the
literature and in signiﬁcantly older patients.
J Global Oncol. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
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Diffuse large B-cell lymphoma (DLBCL) is the most
commonly diagnosed non-Hodgkin lymphoma in
adults.1 It is a heterogeneous disease with varying
clinical outcomes attributable to its biology and molecular pathogenesis. Important prognostic factors for
DLBCL are revised international prognostic index,2 cell
of origin (COO),3,4 presence of MYC and BCL2 rearrangements by ﬂuorescent in situ hybridization or
standard cytogenetics,5 absolute lymphocyte and
monocyte count, and imaging with positron emission
tomography.2,3,6
Alizadeh et al3 described three molecular subgroups
by gene-expression proﬁling (GEP) on the basis of the
COO: germinal center B-cell type (GCB), activated
B-cell (ABC) type, and the unclassiﬁable type. The
GCB type DLBCL is characterized by genetic mutations in BCL2, BCL6, and MYC genes, with epigenetic

modiﬁcations in EZH2 genes.7 Patients with this
subtype of DLBCL have a better prognosis compared
with patients with ABC type when treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP), the standard therapy, still, for
a majority of Kenyan patients with DLBCL.8 Addition of
rituximab results in a remarkable improvement in
5-year overall survival rates (from 60% to 90%) in the
GCB group.9 The ABC-type DLBCL is characterized by
constitutive activation of nuclear factor κ-light-chain
enhancer of activated B-cells (NF-κB) pathway,
a protein complex that controls the transcription of
DNA promoting cell proliferation.7 Receiving CHOP
treatment alone, this subgroup of patients does poorly;
the 5-year overall survival rate is approximately 35%,3
and only modestly improved to 44% with addition of
rituximab.9 The unclassiﬁable group of DLBCL has no
distinct genetic pattern and has a similar prognosis to
the ABC type.3,7,9 It is important to determine COO in
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CONTEXT
Key Objective
To determine the prevalence of MYC/BCL2 double expression, cell of origin (COO), and Epstein-Barr virus status of diffuse
large B-cell lymphoma (DLBCL) cases diagnosed at a tertiary referral laboratory in Kenya. The study highlights the
clinicopathologic characteristics of DLBCL from Kenya using immunohistochemical staining panels.
Knowledge Generated
This study highlights key differences between DLBCL cases diagnosed in Kenya and cases diagnosed in Western countries,
including a younger median age (50 years) at presentation, a higher proportion of non-germinal center B COO DLBCL
(59.4%), and a lower percentage of double-expressing cases (9.7%).
Relevance
The high proportion of poor prognostic non-germinal center B-cell type group from Kenya underscores the need for routine
testing of patients with DLBCL for COO to identify those patients who would beneﬁt from addition of rituximab to their
treatment.

patients with DLBCL who may beneﬁt from newer targeted
therapeutic agents. The agents under investigation include
ibrutinib, lenalidomide, and bortezomib, which target the
NF-κB pathway in non-GCB DLBCL.10-13 The current World
Health Organization classiﬁcation requires the identiﬁcation of GCB and ABC/non-GCB subtypes and incorporation
of the subclassiﬁcation into clinical practice.14
Although GEP is not available in routine practice, robust
immunohistochemistry (IHC) surrogates have been developed for determining COO. The Hans algorithm uses
three antibodies in sequence: CD10, BCL6, and MUM1.15
Tumors with greater than 30% positivity in CD10 are
classiﬁed as GCB, whereas CD10-negative cases are
stained additionally with BCL6 and MUM1. CD10-negative
tumors that are positive for BCL6 and negative for MUM1
(cutoff of 30% staining) are classiﬁed as GCB, whereas any
other combination is considered non-GCB. This algorithm
is the most widely applied and has concordance rates of
80% to 87% with GEP.16 When applied to patients receiving
CHOP alone, the algorithm has demonstrated prognostic
signiﬁcance between the GCB and non-GCB groups.15 This
prognostic distinction diminishes when applied to patients
receiving rituximab with CHOP (R-CHOP).15-19 Most patients in Kenya, as a result of limited resources, receive
CHOP alone as standard chemotherapy8,20; hence, the use
of this IHC algorithm retains important prognostic relevance
in our setting.
Fluorescent in situ hybridization is used to identify speciﬁc
gene rearrangements involving BCL2 and MYC. Concurrent
presence of BCL2 and MYC rearrangements is seen in 6%
to 10% of DLBCL.5,6 Such so-called double-hit lymphomas
have a considerably poorer prognosis, with median survival
rates ranging from only 6 to 13 months.1,2,6,21 IHC for MYC
and BCL2 overexpression has been used in DLBCL
prognostication, using cutoffs of 40% nuclear positivity for
MYC and 50% cytoplasmic positivity for BCL2.5,22 Cases
positive for both markers are termed double expressing and

are seen at a much higher frequency (20% to 30%) than
double-hit lymphomas. Cases positive for both markers
have a poor prognosis that is intermediate between DLBCL
not otherwise speciﬁed and double-hit lymphoma, with
5-year overall survival rates of 10% to 36%.2,5,22-24
Epstein-Barr virus (EBV)-positive DLBCL has increasingly
been reported in immunocompetent patients younger than
50 years.25 Data suggest a varied morphologic spectrum
with better prognostic outlook for EBV-positive DLBCL than
previously described.14
COO and MYC/BCL2 double expression are two crucial
prognostic factors in DLBCL that are recommended in the
routine evaluation and reporting of this lymphoma.14,26
Therefore, our aim in this study was to determine the
prevalence of MYC/BCL2 double expression among cases
of DLBCL diagnosed at Aga Khan University Hospital,
Nairobi (AKUHN), and to classify cases of DLBCL by COO.
To our knowledge, this is the largest East African study to
date describing critical clinicopathologic characteristics of
DLBCL.
METHODS
Formalin-ﬁxed, parafﬁn-embedded tissue blocks of consecutive cases of histologically conﬁrmed DLBCL from
January 1, 2012, to December 31, 2015, were retrieved
from archives in the Pathology Department of AKUHN.
Data on age, sex, and tumor site were abstracted from the
pathology database. Hematoxylin and eosin–stained slides
were reviewed with an appropriate block selected for tissue
microarray (TMA) construction. Three tumor areas were
circled and included in a TMA master block, which also
included control cases of Burkitt lymphoma, plasmablastic
lymphoma, reactive tonsillar tissue, and normal epidermis.
IHC with antibodies (namely, CD3, CD5, CD10, CD20,
CD30, MUM1, BCL6, BCL2, MYC, and Ki67) was conducted on 5-micron TMA sections. The details of the antibodies used are listed in Table 1. IHC was performed on
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TABLE 1. Immunohistochemistry Antibody Speciﬁcations
Antibody

Clone

Species

Control

Dilution

CD3

Polyclonal

Rabbit

Tonsil

Ready to use

Membranous, cytoplasmic

Staining Pattern

Dako*

Vendor

CD5

4C7

Mouse

Tonsil

Ready to use

Membranous, cytoplasmic

Dako

CD10

56C6

Mouse

Tonsil

Ready to use

Membranous, cytoplasmic

Dako

CD20

L26

Mouse

Tonsil

Ready to use

Membranous, cytoplasmic

Dako

CD30

Ber-H2

Mouse

Tonsil

Ready to use

Membranous, cytoplasmic, Golgi

Dako

MUM1

MUM1p

Mouse

Tonsil

Ready to use

Nuclear, cytoplasmic

Dako

BCL6

PG-B6p

Mouse

Tonsil

Ready to use

Nuclear

Dako

BCL2

124

Mouse

Tonsil

Ready to use

Cytoplasmic

Dako

MYC

Y69

Rabbit

Skin

Ready to use

Nuclear

Ventana†

Ki67

MIB1

Mouse

Tonsil

Ready to use

Nuclear

Dako

*A subsidiary of Agilent Technologies, Santa Clara, CA.
†Ventana Medical Systems, Tucson, AZ.

Dako EnVision FLEX Autostainer (Agilent Technologies,
Glostrup, Denmark) according to the manufacturer’s
speciﬁcations.
Scoring, in 10% increments, was done by counting 100
tumor cells at a magniﬁcation of ×400. Cutoffs for positivity
were applied as follows: 30% membrane staining for CD20,
CD10, CD5, and BCL615; 50% cytoplasmic positivity for
BCL25,22; 30% and 40% nuclear positivity for MUM1 and
MYC positivity, respectively5,22; and 20% membrane positivity for CD30.27
Per the Hans algorithm,15 cases in the GCB category were
as follows: CD10-positive cases, CD10-negative but BCL6positive cases, and MUM1-negative cases. Non-GCB patients included all those negative for both CD10 and BCL6
or that were CD10 negative but MUM1 positive. Cases were
considered double-expressing DLBCL when both BCL2
and MYC were positive.5,22 In addition, all cases were
subjected to Epstein-Barr virus-encoded small RNAs
(EBER) in situ hybridization,28 which was performed using
a Leica BOND-III automated immunostainer with a Leica
Bond Ready-to-Use ISH EBER Probe according to manufacturer’s instructions (Leica Biosystems, Buffalo
Grove, IL).
We conducted statistical analysis with SPSS, version 23
(IBM, Armonk, NY) and included descriptions of median
age, sex preponderance, tumor site (whether nodal or
extranodal), and proportions according to COO and MYC/
BCL2 status. The t test was used to calculate the level of
signiﬁcance in the median age and mean Ki67 for the
different groups; Fisher’s exact test was used to calculate
the level of signiﬁcance for correlation between COO, tumor
site, and double expression.
RESULTS
A total of 208 cases were identiﬁed for the study period.
Blocks were retrieved for 183 of the cases, from which 16
were excluded for lack of adequate viable tissue and were

not included in the construction of the TMA blocks. Two
TMA blocks were constructed with a total of 167 cases and
20 controls. After TMA construction, another two cases
were excluded from additional analysis, because of failure
of uptake of any immunostain. A ﬂowchart for the selection
and inclusion of cases and their subsequent evaluation is
listed in Figure 1.
Clinical Characteristics
There were 90 men (54.5%) men and 75 women (45.5%);
the median age at diagnosis was 50 years (range, 20 to
90 years). A total of 95 cases (57.9%) were from nodal
sites, and 69 (42.1%) were extranodal. The mean Ki67
proliferation index was 30% (range, 10% to 100%). These
results are listed in Table 2.

208

Total number of DLBCL cases identified for the study period.
Twenty-five cases had no retrievable blocks.

183

Sixteen cases excluded from tissue microarray construction
because of lack of adequate, viable, or good quality material.

167

Two cases excluded from analysis because of a complete
lack of uptake for any IHC stain.

165

Analyzed for cell of origin, double expression, other prognostic
IHC markers, and EBV by EBER in situ hybridization.

Initial scoring by
PI

Blinded
independent review
by two consultant
histopathologists

Discordant cases
settled via
consensus

Final score given
as either positive
or negative

FIG 1. Flowchart illustrating selection of cases. From 208 cases
identiﬁed in the pathology database, blocks were available for 183
cases, of which 16 were excluded for lack of quality material, leaving
167 cases to be included in the tissue microarray. Two cases did not
take up any immunostain. The ﬁnal total of cases analyzed for MYC/
BCL2 double expression and cell of origin was 165. DLBCL, diffuse
large B-cell lymphoma; EBER, Epstein-Barr virus-encoded small
RNAs; EBV, Epstein-Barr virus; IHC, immunohistochemistry; PI,
principal investigator.
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Double Expression of MYC and BCL2

TABLE 2. Summary of Clinical and Immunophenotypic
Characteristics
Characteristic

No. (%)

Sex
Male

90 (54.5)

Female

75 (45.5)

Total

165

Age, years
Median

50

Range

20-90

Only 18 patients (10.9%) had double expression of both
MYC and BCL2, and the median age of these patients (61
years) was signiﬁcantly higher compared with that of the
non–double-expressing group (49 years; P = .0178).
The mean Ki67 proliferation index for the doubleexpressing group was signiﬁcantly higher than that of the
non–double-expressing group (45% v 29%, respectively;
P = .0309), with no association between double-expression
status and nodal versus extranodal tissue site, sex, or COO
(Table 3).

Site
Nodal

95 (57.9)

Extranodal

69 (42.1)

Total

164

Ki67 proliferation index, %
Mean

30

Range

10-100

Cell of origin
GCB

67 (40.6)

Non-GCB

98 (59.4)

Total

165

Double-expression status
Double expressing

Cell of Origin
All 165 cases were analyzed for COO using the Hans algorithm. CD10 and BCL6 were positive in 29.1% and 44.
8% of cases, respectively, and MUM1 was positive in 43.
3% of cases. Overall, 67 cases (40.6%) were GCB-type
DLCBL and 98 cases (59.4%) were non–GCB-type DLCBL.
There was an association between COO and tumor site, with
a greater likelihood of non-GCB cases being nodal than
extranodal (P = .016). The mean level of Ki67 expression
was higher in the GCB group (36%) compared with the
non-GCB group (26%; P = .0088), with no signiﬁcant
difference in age between the GCB and non-GCB groups
(Table 4).

18 (10.9)

Nondouble expressing
Total

147 (89.1)
165

EBV status
Positive

16 (9.7)

Negative

149 (90.3)

Total

165

IHC proﬁle
CD10

48 (29.1)

Positive

117 (70.9)

Negative

74 (44.8)

BCL6

91 (55.2)

CD5 Expression
All CD5-positive cases stained negative for cyclin D1, excluding the diagnosis of mantle cell lymphoma. Additional
comparison with CD3 staining was made to exclude possible reactive T cells among the tumor cells. Eleven of 121
cases (9.1%) stained positive for CD5, 10 occurring in men,
with no signiﬁcant differences in age, mean Ki67 expression, tumor site, or COO between CD5-positive and
negative cases.
CD30 Expression
Only three of 119 cases (2.5%) were positive for the CD30
antibody. This low number precluded additional subgroup
analysis.

Positive

71 (43.3)

Negative

93 (56.7)

EBV Status

45 (27.3)

Sixteen cases (9.7%) were positive for EBV by EBER in situ
hybridization. Twelve of these cases (75%) were non-GCB
and 12 of the positive cases were seen in nodal sites (10 of
them non-GCB; Table 5).

MUM1
Positive

119 (72.6)

Negative

67 (40.6)

MYC

98 (59.4)

Positive

11 (9.1)

Negative

110 (90.9)

BCL2

3 (2.5)

Positive

119 (97.5)

Abbreviations: EBV, Epstein-Barr virus; GCB, germinal center B;
IHC, immunohistochemistry.

DISCUSSION
To our knowledge, this is the largest study conducted of the
immunophenotypic characteristics of DLBCL in Kenya
evaluating the prevalence of double expression and COO,
as well as the proportion of CD5- and CD30-positive cases.
We also used MYC antibody in evaluation of DLBCL cases in
Kenya.

4 © 2019 by American Society of Clinical Oncology
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TABLE 3. Summary of Results for MYC/BCL2 Double Expression (n =
165)
Characteristic
Negative, No. (%)
Positive, No. (%)
P
Sex

TABLE 4. Summary of Results for Cell of Origin
Characteristic

GCB, No. (%)

Non-GCB, No. (%)

P

.750

Sex
Male

38 (56.7)

52 (50.1)

Male

80 (54.4)

10 (55.6)

Female

29 (43.3)

46 (49.9)

Female

67 (45.6)

8 (44.4)

Total

67

98

147

18

Age, years
47

53

49

61

15.0

15.4

14.79

16.91

Nodal

85 (58.2)

10 (55.6)

Extranodal

61 (41.8)

8 (44.4)

146

18

29

45

Total
Age, years
Median
SD

Median
.0178

Tumor site

Site

Total
Mean Ki67, %

.510

Nodal

31 (46.3)

64 (70.0)

Extranodal

36 (53.7)

33 (30.0)

67

97

36

26

Total
Mean Ki67, %

.016

.0088

.0309
Abbreviations: GCB, germinal center B; SD, standard deviation.

Cell of origin
GCB

63 (42.9)

4 (22.2)

Non-GCB

84 (57.1)

14 (77.8)

147

18

Total

SD

.2161

.074

Abbreviations: GCB, germinal center B; SD, standard deviation.

The median age of 50 years in our study is similar to that
reported by Naresh et al8 and 10 years younger than in
Western populations.1,29,30 In their survey of 95 cases in
sub-Saharan Africa, Naresh et al8 showed a slight male
preponderance (male-to-female ratio of 1.5:1). In an unpublished study, Sherman et al assessed 51 cases of DLBCL
at AKUHN and found no sex predilection but highlighted
that up to 37% of the cases were diagnosed in younger
patients age 30 to 40 years (O. Sherman, personal communication, December 2011). Because only 6% of Kenyans are
older than 55 years, it is reasonable to conclude that as our
population ages, the incidence of DLBCL is likely to increase.
We identiﬁed 10.9% cases as double expressing for both
MYC and BCL2 proteins. This proportion is lower than
reported in other studies, which reported ranges from 20%
to 30%.1,5,22,30 Our double-expressing cases showed
a signiﬁcantly higher Ki67 proliferation index, in keeping
with the tumor biology, a ﬁnding replicated in the same
studies.1,5,22,30 Double-expressing DLBCL also occurs in
slightly older individuals,2 which we also found in the
current study, with a median age of 61 years for patients
with double-expressing DLBCL, compared with 49 years for
patients with non–double-expressing DLBCL (P = .0178).
The older age for double-expressing tumors may also point
to why there was such a low prevalence of this DLBCL
type in our study, the population of which comprised
substantially younger patients. Unlike previous studies,5,22
no association was demonstrated between double expression and COO or site of biopsy. This may be because
this study showed a lower prevalence of double-expressing

tumors and therefore was not powered to demonstrate
these differences.
We found 40.6% of cases to be GCB-type DLBCL, compared with other studies that showed the GCB group to
account for 42% to 54% of DLBCL.17 There were relatively
lower percentages of tumors expressing BCL6 (44.8%) and
CD10 (29.1%), compared with prior studies in which BCL6
was expressed in approximately 60% of tumors and approximately 40% of tumors were positive for CD10.1,30
Similar studies conducted in Japan and China reported
GCB ranges of 32% to 39%, suggesting a geographic
variation in prevalence of this subclass of DLBCL.31 This
study’s cases also had a higher Ki67 proliferation index in
the GCB group compared with the non-GCB group (36% v
26%, respectively; P = .0088). There is conﬂicting evidence
on the impact of a high proliferation index on prognosis,
because the use of chemotherapy has been postulated to
be more effective in rapidly dividing tumors.30 In studies by
Hans et al,15 Choi et al,17 and Visco et al,32 GEP was used as
a gold standard upon which concordance was calculated.
Our study did not have a comparison with GEP. Various
studies conducted using Hans algorithm have failed to
replicate its prognostic utility in patients undergoing
R-CHOP therapy.18 Nevertheless, as a result of the prohibitive cost of rituximab in our setting, most patients with
DLBCL still receive CHOP as the standard therapy. Under
these circumstances, the Hans algorithm as applied here
still bears important prognostic utility in this setting.
Previous studies have been inconsistent in their reporting of
the prevalence of MYC overexpression. A study by Hu et al24
showed a MYC overexpression of 64% (n = 468), whereas
Horn et al33 reported a prevalence of 31.8% (n = 282).
Johnson et al22 demonstrated MYC expression in 29% of
their study cases (n = 167). In the current study, we showed
MYC expression in 27.3% of the cases analyzed, a proportion comparable to that reported by Johnson et al22 and
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TABLE 5. Summary of Results of EBV-Positive Cases
Characteristic

No. (%)

P

Age, years
Median age
Range

41
29-62

resistance to chemotherapeutic agents by altering the tumor microenvironment and reducing apoptosis.35,36 Additional clinical information should be sought in such cases
regarding the patient’s HIV status, because CD5-positive
tumors tend to occur at higher frequency in patients with
HIV.1,35

Cell of origin
GCB
Non-GCB

4 (25)

.0455

12 (75)

Tumor site
Nodal
Extranodal

12 (75)

.0455

4 (25)

Abbreviation: GCB, germinal center B.

Green et al.5 The MYC-positive tumors had higher mean
Ki67 expression compared with MYC-negative cases (43%
v 25%, respectively; P , .001). This is an expected ﬁnding,
because tumors with MYC overexpression are more aggressive and have a higher proliferative capacity.34 This
study showed no preponderance for extranodal sites
among MYC-positive cases, contrary to what has been
demonstrated in other studies.33,34 Results are inconsistent
regarding the prognostic value of MYC protein overexpression alone. Ho and Rodig34 reported poor overall
survival for patients positive for MYC overexpression,
whereas Johnson et al22 and Green et al5 suggest that MYC
overexpression alone does not portend a worse prognosis
unless present in combination with BCL2 overexpression,
as seen in double-expressing lymphomas.
BCL2 protein was overexpressed in 40.6% of the cases in
the current study compared with 50% reported in studies
elsewhere.22,24,33 In a local unpublished study, the percentage of BCL2-positive cases was even lower, at 18%
(n = 51; O. Sherman, personal communication, December
2011). BCL2-positive cases in our study were predominantly non-GCB (61.2%) and seen at a higher frequency in nodal sites (61.2%). These ﬁndings did not reach
statistical signiﬁcance but were consistent with the literature.4,17 BCL2 overexpression does not carry any prognostic
signiﬁcance on its own, especially in the rituximab era.5
CD5-positive cases accounted for 9.1% of cases in our
study, a similar proportion to the 5% to 10% reported in the
literature,35 with 10 of the 11 cases occurring in men. More
cases were seen in extranodal sites, consistent with reported literature,36 although too few cases were seen in our
study to reach statistical signiﬁcance. The same was seen
with COO, for which most CD5-positive cases were nonGCB, a ﬁnding consistent with the literature.1 This subgroup of patients has poorer outcomes, with a 5-year overall
survival of 34% compared with 50% in CD5-negative
DLBCL. These patients also have higher rates of CNS recurrence. 35 It is likely that CD5 expression confers

CD30, positive in Reed-Sternberg cells of classic Hodgkin
lymphoma, is also expressed in anaplastic large-cell lymphoma and a subset of DLBCLs. In one study of 903 patients with DLBCL, 14% were positive for CD30 and were
associated with improved 5-year overall survival regardless
of COO.27 The CD30-positive group also showed unique
molecular signatures associated with downregulation of
NF-κB, which provides a plausible genetic basis for its
superior outcomes, in addition to being amenable to CD30directed monoclonal antibody therapy with brentuximab
vedotin.27 In our study, CD30-positive cases accounted for
only 2.5% of the cases studied, a proportion much lower
than that reported in other studies (10% to 20%).19 Additional studies are recommended to better characterize
the value of routine staining for CD30 antibody in DLBCL in
Kenya.
EBV-positive DLBCL, thought to account for 3% to 15% of
cases of DLBCL, was reported in older (. 50 years) immunocompetent patients and was associated with poorer
outcomes than EBV-negative DLBCL.37 However, recent
data suggest a wider age range of EBV-positive DLBCL, with
better outcomes.25 In our study, approximately 10% of
patients were EBV positive and ranged in age from 29 to
62 years (median age, 41 years). As reported in other
studies, most cases occurred in nodal sites and were of the
non-GCB subtype.38 Data on the immune status and longterm outcome of these patients were not available for this
study and present an opportunity for future studies.
In summary, we report that DLBCL in Kenya occurs in
younger patients (median age, 50 years). Most patients
present with nodal disease; there seems to be no predilection for either sex. Although Hans algorithm used to
classify COO for DLBCL is of limited utility in prognosticating
patients receiving R-CHOP treatment, we still ﬁnd it relevant
in our setting, where most patients receive CHOP as
standard treatment for DLBCL. Of note, 59.4% of our study
patients had the unfavorable non–GCB-cell type of DLCBL,
highlighting a large group of patients who need rituximab
added to their treatment. In addition, these patients may
also be considered in the future for targeted therapies such
as bortezomib and lenalidomide. Double expression for
MYC and BCL2 was seen in only 10.9% of patients. These
patients were substantially older, which may explain in part
the reason for such a low prevalence. Given the poor
prognosis of MYC/BCL2 double expression, we recommend
routine testing for these two markers at diagnosis despite its
lower prevalence in our setting.
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